Literature DB >> 582911

The vascular effects of flunarizine as compared with those of other clinically used vasoactive substances.

J M Van Nueten, J Van Beek, P A Janssen.   

Abstract

Flunarizine, a difluoro derivative of cinnarizine, produces a long-lasting inhibition of calcium-induced contractions of isolated vascular preparations of rabbit and rat. In this regard it is slightly more active than cinnarizine and markedly more active than papaverine, naftidrofuryl, bencyclane, cylandelate, dihydroergotoxine, xantinol nicotinate and pentoxifylline; calcium dobesilate does not inhibit the calcium-induced responses. A long-lasting antivasoconstrictor effect was observed also for cinnarizine. This action of flunarizine is selective for calcium channels in vascular tissue, since it has little effect on the calcium-induced response of myocardial preparations of the cat. Flunarizine has no effect on the rhythmic activity of myogenically active blood vessels; it thus shows a further selective activity to calcium channels activated by vasoconstrictor agents and not for those opened by intrinsic changes in membrane permeability. This dual selectivity implies that flunarizine is a useful reference substance in assessing calcium antagonism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 582911

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

1.  Enhanced reactivity towards flunarizine in cerebrovascular bed of spontaneously hypertensive rats.

Authors:  E Koźniewska
Journal:  Experientia       Date:  1988-03-15

2.  Specific suppression of pentylenetetrazol-induced epileptiform discharges in CA3 neurons (hippocampal slice, guinea pig) by the organic calcium antagonists flunarizine and verapamil.

Authors:  D Bingmann; E J Speckmann
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

3.  Proceedings of the British Pharmacological Society. 10th-12th September, 1980. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

4.  Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia.

Authors:  M G Albizzati; S Bassi; E Calloni; M Sbacchi; R Piolti; L Frattola
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

6.  Inhibition of human platelet functions by cyclandelate.

Authors:  W E van den Hoven; D W Hall
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  A comparison of the effects of the calcium entry blockers, verapamil, diltiazem and flunarizine against contractions of the rat isolated aorta and portal vein.

Authors:  J F Marriott
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.